



POST COVID MANAGEMENT OF ASTHMA IN CHRONIC ASTHMA PATIENT

RAJAT DASH ^a, B. RAY ^{b*}, S. N. DAS ^b AND SWASTIK KUMAR PUROHIT ^a

^aGCP, SBP, Odisha, India.

^bPost Graduate Department, GCP, SBP, Odisha, India.

AUTHORS' CONTRIBUTIONS

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Received: 06 October 2021

Accepted: 12 December 2021

Published: 24 December 2021

Review Article

ABSTRACT

Asthma is defined as a chronic inflammatory disease of the airways. The chronic inflammation is associated with airway hyper responsiveness (an exaggerated airway narrowing response to triggers, such as allergens and exercise), that leads to recurrent symptoms such as wheezing, dyspnea (shortness of breath), chest tightness and coughing. Asthma is associated with T helper cell type-2 (Th2) immune responses, which are typical of other atopic conditions. Various allergic (e.g., dust mites, cockroach residue, furred animals, moulds, pollens) and non-allergic (e.g., infections, tobacco smoke, cold air, exercise) triggers produce a cascade of immune-mediated events leading to chronic airway inflammation. The Present Review Discuss and Focus about the various Risk factor associated with Covid 19 influenced Asthma Patient with their Possible Management.

Keywords: Asthma; allergy; antigene; antibody; immunity; cytokines.

1. INTRODUCTION

We keep new information about the ailment every day, since the first diagnosis of the coronavirus in December 2019 in Wuhan. Currently, the entire world remains going through a severe pandemic and the fight in opposition to the disorder is continuing. World Health Organization (WHO) declared this outbreak as a virus on March eleven, 2020, as the sickness became spreading unexpectedly in many countries [1].

2. DOES ASTHMA INCREASE THE RISK OF COVID-19 ?

Centers for Disease Control and Prevention (CDC) reported that individuals above 65 years old and those with chronic diseases were in the risk group for the COVID-19 [2].

It was also reported that asthma patients with moderate to severe condition were in this risk group. However, the rate of asthma disease was low among the COVID-19 cases, especially in the observational case series from China [3-6]. In a study evaluating the clinical characteristics and allergies of 140 patients from Wuhan, no cases of asthma and allergic rhinitis were reported; however, only 2 cases of urticaria were reported [7]

In this study, the authors suggested that the prevalence of asthma and allergic rhinitis in Wuhan province was 4.2% and 9.7%, respectively [8].

These data were based on China-originated cases. The question comes to mind as to if these results differ in other countries? In a monthly report evaluating hospitalization and characteristics of cases in the

*Corresponding author: Email: crabiswa@gmail.com;

USA, 180 comorbid diseases (12.1%) among the 1482 hospitalized cases were reported [9].

While some meta-analyses reported no data related to asthma [10], some others reported that asthma was related to a high risk of the COVID-19 mortality in hospitals [11]. Moreover, in a 37-year old case with asthma and COVID-19, postmortem lung findings were reported [12]. It was suggested that the patient had diabetes mellitus and was receiving ipratropium bromide and albuterol treatment for asthma. It is noteworthy that the patient was not using inhaler steroids [13-16]. The existence of diffuse alveolar damage and mucous plaques in the patient's lung sections was associated with asthma. Some authors explain the existence of only very few reports related to COVID-19 and asthma due to three possible reasons [17].

During in-vitro studies, it was indicated that pre-treatment administration of budesonide inhibited the HCov-229E replication and cytokine production in human respiratory epithelium [18].

Furthermore, it was shown that ciclesonide blocked the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA replication [19].

There are also studies showing that inhaler steroids disrupt antiviral innate immune responses [20].

There are also clinical studies showing that azithromycin prevents virus-induced asthma attacks [21].

1.1 Definition

Asthma is described as a persistent inflammatory sickness of the airways. The persistent irritation is related to airway hyperresponsiveness (an exaggerated airway narrowing reaction to triggers, which include allergens and exercising), that results in recurrent signs and symptoms such as wheezing, dyspnea (shortness of breath), chest tightness and coughing. Symptom episodes are normally related to big, but variable, airflow obstruction in the lungs that is generally reversible both spontaneously or with appropriate bronchial asthma treatment [22].

3. PATHOPHYSIOLOGY

Asthma is associated with T helper cell type-2 (Th2) immune responses, which are typical of other atopic conditions. Various allergic (e.g., dust mites, cockroach residue, furred animals, moulds, pollens) and non-allergic (e.g., infections, tobacco smoke, cold air, exercise) triggers produce a cascade of immune-

mediated events leading to chronic airway inflammation. Elevated levels of Th2 cells in the airways release specific cytokines, including interleukin (IL)-4, IL-5, IL-9 and IL-13, that promote eosinophilic inflammation and immunoglobulin E (IgE) production by mast cells. IgE production, in turn, triggers the release of inflammatory mediators, such as histamine and cysteinyl leukotrienes, that cause bronchospasm (contraction of the easy muscle in the airways), edema (swelling) and expanded mucous secretion (mucous hypersecretion), which result in the characteristic signs and symptoms of bronchial asthma [22,23]. The mediators and cytokines released during the early phase of an immune response to an inciting allergen, cause a in addition inflammatory response (overdue-section asthmatic response) that leads to further airway irritation and bronchial hyperreactivity [23]. Evidence shows that there can be a genetic predisposition for the improvement of allergies. A quantity of chromosomal areas related to bronchial asthma susceptibility have been diagnosed, together with the ones associated with the manufacturing of IgE antibodies, expression of airway hyperresponsiveness, and the production of inflammatory mediators [24,25]. However, in addition have a look at is needed to decide precise genes involved in allergies as well as the gene-environment interactions which could lead to expression of the ailment [22,23].

3.1 Diagnosis

The prognosis of allergies entails an intensive clinical records, physical examination, and objective checks of lung function (spirometry preferred) to affirm the prognosis. Bronchoprovocation undertaking testing and assessing for markers of airway inflammation can also be useful for diagnosing the ailment, in particular while objective measurements of lung characteristic are normal notwithstanding the presence of allergies signs [26,27].

4. ASTHMA MANAGEMENT :- GENERAL PRINCIPLES

The long-time period goals of bronchial asthma control are to acquire desirable symptom manage and to minimize destiny hazard of exacerbations, constant airflow dilemma and aspect results of remedy. To this cease, setting up a partnership between the affected person and health care issuer is critical, and a shared-care approach – in which sufferers play an energetic function within the control of their asthma – is related to progressed outcomes [27]. Similarly, “controlbased” control techniques, wherein treatment is adjusted based on the affected person's response in terms of both symptom manipulate and future risk of

exacerbations and side results, were shown to improve bronchial asthma results [28].

4.1 Patient Education and Self-Management

Providing patients with training and inhaler skills, encouraging adherence to medicine, and imparting schooling in allergies self-control are crucial steps of disorder management. These are quality accomplished thru a partnership among the affected person and their fitness care providers [29]. Poor inhaler technique ends in terrible asthma control and will increase chance of exacerbations and damaging outcomes [30]. Yet, as much as 70–eighty% of sufferers are unable to use their inhaler correctly and maximum of them are ignorant of their hassle using the inhaler tool. Strategies to make certain powerful use of gadgets encompass: choosing the maximum suitable tool based totally on to be had options, affected person abilities and cost; displaying the patient how to use the device correctly; and checking (and ultimately correcting) inhaler method, and re-check it frequently (proof A). Poor adherence to medicines occurs in about 50% of asthmatic sufferers on long-time period remedy [31]. Factors contributing to poor adherence consist of: medication/regimen elements (e.G., problems using the tool), unintentional terrible adherence (e.G., (e.G., misunderstanding about instructions), notion that treatment isn't necessary, or concerns about aspect results. Interventions inclusive of shared selection-making and prescription of once-day by day (vs. Two times-daily) medications had been proven to enhance treatment adherence in allergies [32]. Providing patients, their circle of relatives, and other carers with allergies information is in addition crucial and the GINA internet site (www.Ginasthma.Org) carries instructional materials in addition to hyperlinks to several bronchial asthma websites. Guided self-management (either “patient-directed” or “medical doctor-directed”) is effective in controlling signs and minimizing the risk of exacerbations and need for health care utilization (evidence A) [33]. However, best self-control education requires 3 additives: self-monitoring of symptoms and/or PEF; a written asthma motion plan, which suggests patients how to make brief-term modifications to their remedy in response to changes of their signs and/or PEF, and describes whilst to get entry to medical care; and everyday comply with-up consultations with a Fitness care issuer to assess allergies manipulate and treatment problems (evidence A) [34]. In patients with severe disease at high threat of hospitalization, follow-up through tele healthcare can be useful .

4.2 Managing Asthma with Comorbidities and in Special Settings

A number of comorbidities are generally found in sufferers with allergies, mainly people with difficult-totreat or extreme allergies. Recognition and active control of comorbidities is crucial due to the fact they will contribute to symptoms, impaired excellent of lifestyles, and negative asthma control [35].

4.2.1 Obesity

Asthma is more tough to govern in obese sufferers [34,35], and this may be due to a exclusive form of airway infection, concomitant obstructive sleep apnea and GER, or mechanical factors. However, due to other ability causes of dyspnea and wheezing in overweight patients, the prognosis of bronchial asthma ought to be carefully reviewed. Similar to other asthmatic patients, ICSs are the mainstay of treatment, although their response can be reduced [35]. Weight loss is an crucial A part of the treatment plan in obese patients (evidence B) [36,37]. Despite the fact that their response may be decreased [35]. Weight loss is an crucial a part of the treatment plan in overweight sufferers (evidence B) [36].

4.2.2 GER disease

Symptoms and/or prognosis of GER ailment are more not unusual in asthmatic patients in comparison with the gen-eral population [33]. However, asymptomatic GER is an unlikely purpose of poorly managed bronchial asthma, and there is no fee in screening patients with uncontrolled asthma for GER (evidence A). Patients with poorly managed bronchial asthma ought to be dealt with with anti-reflux medicine (e.G., proton pump inhibitors or motility dealers) handiest if they have additionally symptomatic reflux (proof A) [34].

4.2.3 Athletes

Athletes, especially the ones competing at high level, have an multiplied incidence of various respiratory conditions, consisting of allergies. In these patients, asthma is characterized by less correlation among signs and pulmonary characteristic, better lung volumes and expiratory flows, and extra trouble in controlling symptoms. Exposure to air pollutants and education in intense cold ought to be avoided [36,25]. ICSs are the remedy of choice, while minimizing the use of β 2-agonists will keep away from the development of tolerance [35].

4.2.4 Management of exacerbations in the emergency department

Lung function (either PEF or FEV1) and oxygen saturation (preferably with the aid of pulse oximetry) should be carefully monitored until a clean reaction to treatment has come about. Saturation levels <ninety two% respiratory room air sign he want for aggressive therapy. Arterial blood gas measurements must be considered for sufferers with a PEF or FEV1 <50% predicted SpO2 <92% or individuals who do no longer respond to initial remedy. Chest X-ray is not robotically performed, and have to be taken into consideration if a complicating or alternative method is suspected or for patients now not responding to treatment.

Titrated low go with the flow oxygen remedy must be administered through nasal cannulae or mask to achieve oxygen saturation of 93–ninety five%. Inhaled SABA ought to be administered regularly, and the maximum price-powerful shipping is by way of pMDI with a spacer (evidence A) , although in Switzerland, SABA are more likely to be administered via a nebulizer device. On the other hand, the ordinary use of intravenous β 2-agonists in this placing isn't recommended (evidence A) . Systemic corticosteroid (oral prednisone forty–50 mg for five–7 days or intravenous equivalent methylprednisolone) velocity decision of exacerbations and prevent relapse, and need to be utilized in all but the mildest exacerbations (proof A) . Their use is mainly critical if initial SABA treatment fails to supply durable development in symptoms or if the exacerbations developed even as the patient was taking OCS. A 5- to 7-day path in adults and a three- to five-day route in children are typically enough (evidence B) .

Early management of excessive-dose ICS (e.G., in the first hour after presentation) reduces the want for hospitalization in patients not receiving systemic corticosteroids (proof A) . On discharge home, the majority of sufferers should be prescribed everyday ICS remedy as ICS-containing medications lessen the hazard of asthma-related loss of life or hospitalizatiIpratropium bromide (a short-appearing anticholinergic) and SABA are associated with fewer hospitalizations and more development in PEF and FEV1 as compared with SABA on my own . In sufferers with FEV1 <25% anticipated at presentation and people who fail to respond to initial remedy and have persistent hypoxia, intravenous magnesium sulfate (2 g infusion over 20 min) ought to be considered (evidence A) [37,38]. The proof concerning the function of noninvasive air flow is weak and no specific recommendation has been made

on this regard. Prior to discharge from the emergency branch or health facility to home, a follow-up appointment inside 1 week ought to be organized, and strategies to enhance allergies management (e.G., medications, inhaler techniques, and written action plan) must be addressed [39,40]. Patients who have been hospitalized for asthma, or who time and again present to an acute care a pulmonologist .

5. EFFECTS OF COVID-19 ON CHILDREN, RESPIRATORY ADMISSIONS, AND HEALTH CARE UTILIZATION

The most regularly occurring presentation of COVID-19 fashionable very young character consists of kingdom of high temperature or agitation, cough, rhinorrhea, tachypnea, fatigue, and gastrointestinal sign of illness or hassle. patients under the age of 18 y accompanying SARS-CoV-2 undergo less excessive sign of infection or hassle, accompanying a large plurality lifestyles asymptomatic or mildly indicative [41,42].

uncommon manifestations which includes multisystem infammatory disorder in youngsters and teenagers are described. cautioned motives for milder ailment in children in all likelihood include reduced ACE2expression in respiration epithelium,a robust innateimmune response, go safety from other respiration infections (e.g., rhinovirus) and fewer comorbidities [43]. Concomitant viral breathing infection can gift with fever and nasal congestion and can be pressured with COVID-19 contamination. consequently, the diagnostic PCR testing is crucial in diferentiating COVID-19 from other breathing infections [41]. extra recent COVID-19 information posted from one Indian medical institution revealed that 56.five% of the providing children were managed as outpatients and fifty nine% of these needing admission had comorbidities [44]. average, forty two% of the children admitted as COVID superb have been hypoxic with 18% having ARDS. Mortality charge was 11.4% of the admitted youngsters and a majority of kids who died had been over 10 y vintage, had been malnourished and/or had comorbidities which includes malnutrition, tuberculosis, malignancies, and so on. In another multicenter retrospective take a look at from India, a massive majority of kids had slight ailment and slight-tosevere disorder turned into found in 9.7% of the supplying children. among those, 44% of the children had comorbidities with a mortality of 3.2%. In every other have a look at, a whole lot milder symptoms were reported. therefore, there seems to be a clean demographic diference in severity primarily based on various factors [42]. A signifcant discount in medical

institution and emergency care admissions of youngsters with breathing conditions for non-COVID reasons has been described for the duration of the COVID-19 pandemic. even as a number of those can be due to a discount in seasonal breathing infections and transmission because of decreased human motion, a number of those might be genuine lack of get entry to to move and reduced non-COVID emergency facilities in below-resourced and low-middle profits countries. The decreased quantity of youngsters offering to usually busy tertiary respiratory clinics in the course of the pandemic is regarding [45].

5.1` Asthma as a Risk Factor for Severe COVID-19

there was an preliminary situation that people with bronchial asthma were more liable to extreme COVID infection because of the affiliation of bronchial asthma with viral infections and also risk that viral aerosol deposition is more commonplace in them. Early records from China advised that asthma isn't a chance thing for extreme infection [46]. however, studies from the United Kingdom have identified a better risk of health center mortality from COVID-19 for sufferers with an underlying analysis of allergies [47].

To similarly complicate the query, allergies has additionally been hypothesized to be defensive of extreme COVID19 signs, as an analysis of fifty seven studies which includes over 580,000 patients found a 14% danger-reduction ratio of obtaining COVID-19 and a 13% decrease in hospitalizations [48]. records on the relationship between asthma and COVID-19 in pediatric sufferers are lacking, with one systemic evaluation declaring that there are insufficient data to determine if there is a true threat [49].

5.2 Effects of COVID-19 on Acute Asthma Exacerbations

Viral infections are one of the most commonplace triggers for allergies exacerbations. fairly, facts from diverse nations have shown decreased acute bronchial asthma shows during the pandemic. One observe looking on the emergency branch (ED) visits at a big educational center in US observed that ED visits for allergies decreased 80% at once following the government mandated stay-at-domestic order . comparable traits had been visible in developing nations [50]. The lower become possibly a result of pandemic mitigation measures, reduced exposure to triggers along with aeroallergens, seasonal respiratory virusesart of faculty there's a possibility that boom in surge of viral infections which in reality can trigger allergies fare ups.more than one towns including Queensland in Australia have validated improved

seasonal viral such as RSV and rhinovirus infections out of season [51].

5.3 Risk Factors Associated with Asthma

Allergic rhinitis and atopy are essential risk elements for allergies and its remedy want nasal congestion seen from allergic rhinitis may be confused with COVID-19 symptoms and must be tested if required. Obstructive sleep apnea (OSA),asystemicinflammatory problems dueto dysfunctional respiratory throughout sleep can get worse airway infammation in asthmatics and has been defined as a ability risk issue for excessive COVID-19infection in adults [52]. subsequently, kids with obesity and bronchial asthma are at better danger of OSA, which similarly will increase the chance of excessive COVID-19 and hence these conditions want to be evaluated and treated as it should be. at some point of the COVID19 pandemic weight problems fees have improved from thirteen.7% to 15.4%, with the best increase visible in Hispanic/Latino and non-Hispanic black sufferers 5 to nine y old [53]. Sleep deprivation and fragmentation can modify immune response andmay probably increase the chance of extreme COVID-19; therefore, merchandising of desirable sleep hygiene practices, further to management of hysteria and despair and dysfunctional breathing are all regarded as important adjuncts to asthma management. thereis a well documented affiliation among psychosocial risk factors and negative bronchial asthma manipulate [54]. during the pandemic, kids, and young people with bronchialasthma have reported excessive fees anxiety depression, and submit-demanding pressure [55].

6. CONCLUSION

The treatment of Asthma is now a days most advance by Different Pulmonary Drug Delivery Device. But Unfortunately it is so severe when Co exist with Covid 19.Research is going on in this field to manage successfully by existing drug therapy.Many new drugs are under trial which are meant for future hope.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020.

- Available:<https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
Accessed 15th Mar 2020.
2. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19) situation summary Available: <https://www.cdc.gov/coronavirus/2019-ncov/index.html>
Accessed 15th Mar 2020
 3. Coates AL, Wanger J, Cockcroft DW, Culver BH; and the Bronchoprovocation Testing Task Force: Kai-Håkon Carlsen, Diamant Z, Gauvreau G, Hall GL, Hallstrand TS, Horvath, de Jongh FHC, Joos G, Kaminsky DA, Laube BL, Leuppi JD, Sterk PJ: ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. *Eur Respir J*. 2017;49:pii 1601526.
 4. Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. *Chest*. 2002;121:1036–1041.
 5. Travers AH, Milan SJ, Jones AP, Camargo CA Jr, Rowe BH. Addition of intravenous beta(2)-agonists to inhaled beta(2)-agonists for acute asthma. *Cochrane Database Syst Rev* 2012;12:CD010179.
 6. Manser R, Reid D, Abramson M: Corticosteroids for acute severe asthma in hospitalised patients. *Cochrane Database Syst Rev*. 2001; 1:CD001740.
 7. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy* 2020. DOI: 10.1111/all.14238
 8. Huang K, Yang T, Xu J, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. *Lancet*. 2019;394:407-18.
 9. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(15):458-64.
DOI: 10.15585/mmwr.mm6915e3.
 10. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Arch Acad Emerg Med*. 2020;8(1):e35. ECollection; 2020.
 11. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. COVID19 SARS-CoV-2 preprints from medRxiv and bioRxiv 2020.
DOI: 10.1101/2020.05.06.20092999
 12. Konopka KE, Wilson A, Myers JL. Postmortem lung findings in an asthmatic with coronavirus disease 2019 (COVID19). *Chest* 2020 pii: S0012-3692(20)30775-3.
DOI: 10.1016/j.chest.2020.04.032
 13. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database Syst Rev*. 2007;3:CD000195.
 14. Hasegawa T, Ishihara K, Takakura S, Fujii H, Nishimura T, Okazaki M, Katakami N, Umeda B: Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. *Intern Med*. 2000;39: 794–797.
 15. Jones AM, Munavvar M, Vail A, Aldridge RE, Hopkinson L, Rayner C, O'Driscoll BR: Prospective, placebo-controlled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. *Respir Med*. 2002;96:950–954.
 16. Edmonds ML, Milan SJ, Camargo CA Jr, Pollack CV, Rowe BH: Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. *Cochrane Database Syst Rev*. 2012;12:CD002308.
 17. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? *Lancet Respir Med*. 2020;8(5):436-8.
 18. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. *Respir Investig* 2020. Epub 2020/02/26.
 19. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. *bioRxiv* 2020.
DOI: 10.1101/2020.03.11.987016.
 20. Simpson JL, Carroll M, Yang IA, Reynolds PN, Hodge S, James AL, et al. Reduced antiviral interferon production in poorly

- controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. *Chest*. 2016;149(3):704-13.
21. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. *bioRxiv* 2020. DOI: 10.1101/2020.03.11.987016.
 22. Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, doubleblind, placebo-controlled trial. *Lancet*. 2017;390(10095):659- 68.
 23. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available: www.ginaasthma.org
 24. Williamson E, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *medRxiv*. 2020. DOI:<https://doi.org/10.1101/2020.05.06.20092999>
 25. Pelletier JH, Rakkar J, Au AK, Fuhrman D, Clark RSB, Horvat CM. Trends in US pediatric hospital admissions in 2020 compared with the decade before the COVID-19 pandemic. *JAMA Netw Open*. 2021;4:e2037227.
 26. Lemanske RF, Busse WW: Asthma: Clinical expression and molecular mechanisms. *J Allergy Clin Immunol*. 2010;125:S95-102.
 27. Loughheed MD, Lemièrre C, Dell SD, Ducharme FM, Fitzgerald JM, Leigh R, Licskai C, Rowe BH, Bowie D, Becker A, Boulet LP: Canadian Thoracic Society asthma management continuum: 2010 consensus summary for children six years of age and over, and adults. *Can Respir J*. 2010;17:15-24.
 28. Kaplan AG, Balter MS, Bell AD, Kim H, McIvor RA: Diagnosis of asthma in adults. *CMAJ*. 2009; 181:E210-E220.
 29. Hahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA. A 10 year asthma programme in Finland: major change for the better. *Thorax*. 2006;61:663-670.
 30. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized openlabel study. *BMC Pulm Med*. 2010;10:1.
 31. Powell H, Gibson PG. Options for self-management education for adults with asthma. *Cochrane Database Syst Rev*. 2003;1:CD004107.
 32. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, Bauman A, Hensley MJ, Walters EH. Self-management education and regular practitioner review for adults with asthma. *Cochrane Database Syst Rev*. 2003;1:CD001117.
 33. McLean S, Chandler D, Nurmatov U, Liu J, Pagliari C, Car J, Sheikh A. Telehealthcare for asthma. *Cochrane Database Syst Rev*. 2010;10:CD007717.
 34. Boulet LP: Influence of comorbid conditions on asthma. *Eur Respir J*. 2009;33:897-906.
 35. Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS, Ekelund J, Illueca M, Beckman O, Sostek MB: Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. *Am J Respir Crit Care Med*. 2006;173:1091-1097.
 36. Hatoun J, Correa ET, Donahue SMA, Vernacchio L. Social disHatoun J, Correa ET, Donahue SMA, Vernacchio L. Social distancing for COVID-19 and diagnoses of other infectious diseases in children. *Pediatrics*. 2020;146:e2020006460.
 37. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. *Thorax*. 2005;60: 740-746.
 38. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA Jr. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. *Cochrane Database Syst Rev*. 2000;2:CD001490.
 39. Gallegos-Solórzano MC, Pérez-Padilla R, Hernández-Zenteno RJ. Usefulness of inhaled magnesium sulfate in the coadjuvant management of severe asthma crisis in an emergency department. *Pulm Pharmacol Ther*. 2010;23:432-437.
 40. Schatz M, Rachelefsky G, Krishnan JA: Follow-up after acute asthma episodes: what improves future outcomes? *Proc Am Thorac Soc*. 2009;6:386-393.
 41. Ding Y, Yan H, Guo W. Clinical characteristics of children with COVID-19: a meta-analysis. *Front Pediatr*. 2020;8:431.
 42. Nallasamy K, Angurana SK, Jayashree M, et al. Pediatric COVID Management Team. Clinical profile, hospital course and outcome of children with COVID-19. *Indian J Pediatr*. 2021;88:979-84

43. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. *Pediatr Infect Dis J.* 2020;39:355–68
44. Singh P, Attri K, Mahto D, et al. Clinical profile of COVID–19 illness in children-experience from a tertiary care hospital. *Indian J Pediatr.* 2021. DOI:<https://doi.org/10.1007/s12098-021-03822-5>
45. Lodha R, Kabra SK. COVID–19 pandemic: impact on health care of children and the urgent need to restore regular healthcare services. *Indian J Pediatr.* 2021;88:225
46. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID–19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020;146:110–8.
47. Sunjaya AP, Allida SM, Di Tanna GL, Jenkins C. Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID–19: systematic review and meta-analysis. *J Asthma.* 2021;1–14. DOI:<https://doi.org/10.1080/02770903.2021.1888116>.
48. Castro-Rodriguez JA, Forno E. Asthma and COVID–19 in children: a systematic review and call for data. *Pediatr Pulmonol.* 2020;55:2412–8.
49. Simoneau T, Greco KF, Hammond A, Nelson K, Gafn JM. Impact of the COVID–19 pandemic on pediatric emergency department utilization for asthma. *Ann Am Thorac Soc.* 2020;18:717–9.
50. Alsulaiman JW, Kheirallah KA, Ajlony MJ, Al-Tamimi TM, Khasawneh RA, Al-Natour L. Paediatric asthma exacerbation admissions and stringency of non-pharmaceutical interventions: results from a developing country. *Int J Clin Pract.* 2021;75:e14423.
51. Foley DA, Yeoh DK, Minney-Smith CA, et al. The interseasonal resurgence of respiratory syncytial virus in Australian children following the reduction of coronavirus disease 2019-related public health measures. *Clin Infect Dis.* 2021. DOI:<https://doi.org/10.1093/cid/ciaa1906>.
52. Strausz S, Kiiskinen T, Broberg M, et al. Sleep apnoea is a risk factor for severe COVID–19. *BMJ Open Respir Res.* 2021;8:e000845.
53. Jenssen BP, Kelly MK, Powell M, Bouchelle Z, Mayne SL, Fiks AG. COVID–19 and changes in child obesity. *Pediatrics.* 2021;147:e2021050123.
54. Weinstein SM, Pugach O, Rosales G, Mosnaim GS, Walton SM, Martin MA. Family chaos and asthma control. *Pediatrics.* 2019;144:e20182758.
55. Marques de Miranda D, da Silva Athanasio B, Sena Oliveira AC, Simoes-E-Silva AC. How is COVID-19 pandemic impacting mental health of children and adolescents? *Int J Disaster Risk Reduct.* 2020;51:101845.